HealthBridge to Support Apligraf for Organogenesis
October 27 2003 - 11:53AM
PR Newswire (US)
HealthBridge to Support Apligraf for Organogenesis BRAINTREE,
Mass., Oct. 27 /PRNewswire/ -- HealthBridge, a reimbursement and
product support services company, was selected by biotechnology
company Organogenesis to manage the APLIGRAF(R) Reimbursement
Support Center. Apligraf is used as a wound-healing therapy for the
treatment of diabetic foot ulcers and venous leg ulcers.
Organogenesis was the first company to develop and gain FDA
approval for a mass-produced product containing living human cells.
Through the APLIGRAF(R) Reimbursement Support Center, HealthBridge
answers questions from patients and physicians' offices about
insurance coverage. The goal is to simplify the process of securing
reimbursement for APLIGRAF(R) while ensuring access to the drug for
patients who need it. "We're excited about the opportunity to work
with Organogenesis and support the APLIGRAF(R) Reimbursement
Support Center," said John J. Seman, president & CEO of
HealthBridge. "Providing reimbursement support to patients and
physicians allows the physicians to focus on healing the patient,
and the patient on getting well. We take the complexities out of
the insurance system and enable the patient to receive their
prescribed treatment." About HealthBridge HealthBridge is a
dynamic, growth-oriented company offering services, which simplify
the complexities of medical reimbursement. The company provides
pharmaceutical, biotechnology and medical device companies with
innovative reimbursement solutions that support product goals and
educate physicians, payers and patients. HealthBridge is located in
Braintree, Massachusetts. For more information, please visit
http://www.healthbridgeinc.com/ or call 888.558.2850. Contact:
Stacie Madden (781) 926-3614 DATASOURCE: HealthBridge CONTACT:
Stacie Madden of HealthBridge, +1-781-926-3614, Web site:
http://www.healthbridgeinc.com/
Copyright